{"id":55802,"date":"2023-04-13T19:03:06","date_gmt":"2023-04-13T17:03:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/certis-oncology-solutions-launches-predictive-analytics-platform\/"},"modified":"2023-04-13T19:03:06","modified_gmt":"2023-04-13T17:03:06","slug":"certis-oncology-solutions-launches-predictive-analytics-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/certis-oncology-solutions-launches-predictive-analytics-platform\/","title":{"rendered":"Certis Oncology Solutions Launches Predictive Analytics Platform"},"content":{"rendered":"
\n

\nBioinformatics solution combines artificial intelligence, machine learning, and functional testing to elevate precision cancer treatment<\/b><\/p>\n

<\/a><\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#ArtificialIntelligence<\/a>–Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the launch of CertisAI\u2122, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers. This pan-cancer solution can accelerate drug discovery and companion diagnostics development.<\/p>\n

\nUnlike common single-biomarker strategies often employed in precision medicine, CertisAI\u2122 uses multivariate machine learning algorithms to capture the nuance of biomarker interactions and bring greater accuracy to predictions of drug efficacy.<\/p>\n

\n\u201cWhen it comes to understanding how to treat a person\u2019s cancer, identifying oncogenic DNA mutations is just scratching the surface,\u201d said Peter Ellman, Certis President and CEO. \u201cThis common approach to precision medicine isn\u2019t capturing the nuance of gene expression levels or the complex interrelationships between multiple genetic features. These dynamics are what govern tumor response to any given therapy, but the complexity involved is too great for any human to grapple with. Computer models can,\u201d he said.<\/p>\n

\nBringing AI Support to Cancer Therapeutics Development<\/b><\/p>\n

\nDespite great progress in cancer research, fewer than 4% of oncology drugs that enter clinical trials are ultimately approved for use. Many factors contributing to this \u201ctranslation gap\u201d in cancer therapeutics could be mitigated by better-informed decision-making early in the development process. With CertisAI\u2122, researchers can effectively replace many discovery screening studies with in silico<\/i> predictions, and save time and money by bringing computer-aided insight to a variety of drug development challenges, such as:<\/p>\n